Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$5.64B+144.72%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian James McNamara
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 24,535
- Beta
- 0.24
- Country
- GB
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.87
Financials
Revenue
$5.64B+144.7%Net Income
$767.62M+229.5%EBITDA
$1.52B+179.8%Free Cash Flow
$791.80M+31.5%EPS (diluted)
$0.17+237.3%Shares Outstanding (diluted)
4.46B-3.4%Operating Expenses
$2.38BCash & Debt
$821.01MReturn of Capital
$899.59MRevenue by Segment (annual)
$2.86BDividend per Share
$0.06Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.03B | $1.67B | $0.37 |
| 2024 | $11.23B | $1.44B | $0.32 |
| 2023 | $11.30B | $1.05B | $0.24 |
| 2022 | $10.86B | $1.06B | $0.24 |
| 2021 | $9.54B | $1.39B | $0.30 |
| 2020 | $9.89B | $1.15B | $0.24 |
| 2019 | $8.48B | $655.00M | $0.14 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from HLN's reported EPS growth of 17.6% a year over 6 years.
- EPS in 5 years
- $0.83
- Implied price
- $16.70
- Return from $9.07
- 13.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.30 — -8.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| 7.6% | -3.7% | 0.1% | 3.4% | 6.3% | 8.9% |
| 12.6% | 0.7% | 4.7% | 8.2% | 11.2% | 14.0% |
| 17.6% | 5.2% | 9.4% | 13.0% | 16.2% | 19.1% |
| 22.6% | 9.7% | 14.0% | 17.8% | 21.1% | 24.1% |
| 27.6% | 14.1% | 18.7% | 22.6% | 26.1% | 29.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (9)
- Newszacks.com·5d ago·Negative
ASAIY vs. HLN: Which Stock Is the Better Value Option? Investors with an interest in Consumer Products - Discretionary stocks have likely encountered both Sendas Distribuidora S.A. Sponsored ADR (ASAIY) and Haleon PLC Sponsored ADR (HLN).
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Haleon plc (HLN) Q3 2026 Sales/Trading Call Transcript Haleon plc (HLN) Q3 2026 Sales/Trading Call Transcript
View source ↗ - Newszacks.com·24d ago·Negative
ASAIY or HLN: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Consumer Products - Discretionary sector might want to consider either Sendas Distribuidora S.A. Sponsored ADR (ASAIY) or Haleon PLC Sponsored ADR (HLN).
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Haleon Launches ‘Haleon Health House,' a One-Day Interactive Wellness Pop-Up in Toronto Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing
View source ↗ - Newsprnewswire.com·41d ago·Neutral
Only Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore Nostalgia-fueled experience introduces Excedrin Rapid Relief, providing fast relief of tough pain that starts in as little as 15 minutes Key Takeaways: Excedrin is introducing My Little Headache, a nostalgic digital-pet experience inspired by the handheld toys of the late '90s and early 2000s, capitalizing on the renewed popularity of digital pets among nostalgia-seeking consumers The interactive experience turns he
View source ↗ - Newsreuters.com·80d ago·Neutral
Haleon secures better shelf space at Walmart, Target in bid to boost market share Sensodyne toothpaste maker Haleon has quietly negotiated better spots on shelves at U.S. retailers including Walmart and Target , to gain more visibility at a at a time when mounting grocery bills are hitting shopper spending.
View source ↗ - Newsproactiveinvestors.co.uk·90d ago·Positive
Jefferies raises Haleon price target to 410p on margin strength Jefferies has raised its price target for Haleon (Haleon PLC (LSE:HLN, NYSE:HLN), the consumer health company behind Sensodyne and Advil, to 410p from 400p, maintaining its Buy rating. The broker highlighted a 70 basis point margin beat in the first half of the year, though it warned this revived concerns about whether Haleon was investing enough behind growth.
View source ↗ - Newsprnewswire.com·95d ago·Positive
…s, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes LONDON, Aug. 19, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the pricing terms, expiration and results of the offer to buy back any and all of the outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 (the "Notes") of Haleon US Capital LLC's (the "Offeror"), the Company's wholly owned subsidiary (the "Tender Offer"). The Tender Offer has been made upon …
View source ↗ - Newsprnewswire.com·103d ago·Positive
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes LONDON, Aug. 11, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy back any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. Bondholders will receive a price equal to the Total Consideration based on the Reference Yield and the Fixed Spread plus Accrue
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $0.28 per share
Typical surprise +3.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.28 vs $0.27beat
- Wed, Feb 25$0.26 vs $0.25beat
- Thu, Jul 31$0.24 vs $0.24miss
- Thu, Feb 27$0.23 vs $0.22beat
- Thu, Oct 31$0.23 vs $0.11beat
- Wed, May 1$0.12 vs $0.11beat
Estimates and results for HLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (34d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed May 14, 2025 (35d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jun 8, 2024 (19d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (32d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (33d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (31d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Josh Gottheimerhouse · NJ05 · disclosed Apr 20, 2023 (20d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (42d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
